Celyad Oncology (CYAD) Short Interest Ratio & Short Volume

Short interest is the volume of Celyad Oncology shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 154,600 shares of CYAD short. Learn More on Celyad Oncology's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CYAD shares currently have a short interest ratio of 21.0. Learn More on Celyad Oncology's short interest ratio.

Celyad Oncology saw a decrease in short interest in the month of October. As of October 31st, there was short interest totaling 154,600 shares, a decrease of 4.4% from the previous total of 161,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Celyad Oncology: Orgenesis Inc. (0.87%), Pieris Pharmaceuticals, Inc. (0.14%), Aytu BioPharma, Inc. (6.73%), Avalo Therapeutics, Inc. (7.62%), NeuroBo Pharmaceuticals, Inc. (1.93%), Cocrystal Pharma, Inc. (0.07%), VBI Vaccines Inc. (1.30%), Talphera, Inc. (0.70%), Kiora Pharmaceuticals, Inc. (0.71%), Minerva Neurosciences, Inc. (0.74%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($3.81 billion), Charter Communications, Inc. ($3.04 billion), T. Rowe Price Group, Inc. ($1.98 billion), PG&E Co. ($1.92 billion), Lucid Group, Inc. ($1.90 billion), Coinbase Global, Inc. ($1.75 billion), Roblox Co. ($1.58 billion), Rivian Automotive, Inc. ($1.54 billion), Diamondback Energy, Inc. ($1.53 billion), and Old Dominion Freight Line, Inc. ($1.47 billion). View all of the most shorted stocks.

Short selling CYAD is an investing strategy that aims to generate trading profit from Celyad Oncology as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Celyad Oncology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CYAD, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYAD, twice per month. The most recent reporting period available is October, 31 2022.